Saltar para:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Início > Publicações > Visualização > Facilitation of noradrenaline release by activation of adenosine A(2A) receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery

Publicações

Facilitation of noradrenaline release by activation of adenosine A(2A) receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery

Título
Facilitation of noradrenaline release by activation of adenosine A(2A) receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery
Tipo
Artigo em Revista Científica Internacional
Ano
2004
Revista
Vol. 63
Páginas: 739-746
ISSN: 0008-6363
Classificação Científica
FOS: Ciências médicas e da saúde > Medicina clínica
Outras Informações
ID Authenticus: P-000-8N2
Abstract (EN): Objective: The present work is aimed at elucidating the signalling pathway(s) triggered by activation of A(2A) receptors involved in the facilitation of noradrenaline release in rat tail artery as an attempt to clarify their role in the cardiovascular system. Methods: Electrically evoked (5 Hz, 100 pulses, 1 ms) tritium overflow was evaluated in preparations of rat tail artery, pre-incubated with [H-3]-noradrenaline (0.1 muM), in the absence or in the presence of adenosine receptor agonists and antagonists and/or activators and inhibitors of phospholipase C (PLC)-protein kinase C (PKC) and of adenylate cyclase (AC)-cyclic adenosine-3',5'-monophosphate (cAMP)-protein kinase A (PKA) pathways. Results: Activation of A(2A) receptors by 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680; 100 nM) enhanced tritium overflow, an effect prevented by the A2A receptor antagonist 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3]-1,2,4-triazolo[1,5]pyrimidine (SCH 58261; 20 nM), by the protein kinase A (PKA) inhibitor N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide (H-89; 1 muM), or the PKC inhibitor 2-(8-[(dimethylamino)methyl-6,7,8,9-tetrahydropyrido[1,2]indol-3-yl]-3-(1-methylindol-3-yl)maleimide (Ro 32-0432; 1 muM). The PKC activator phorbol 12-myristate 13-acetate (PMA; 1 muM) and the PKA activator 8-bromo-cAMP (0.5 mM) also enhanced tritium overflow. The effect caused by PMA was blunted both by Ro 32-0432 and by H-89 whereas that caused by 8-bromo-cAMP was only prevented by H-89. Conclusions: In rat tail artery, the A(2A) receptor-mediated facilitation of noradrenaline release requires activation of both PKC and PKA, and PKA activation seems to occur downstream of PKC activation.
Idioma: Inglês
Tipo (Avaliação Docente): Científica
Contacto: jorge.goncalves@ff.up.pt
Nº de páginas: 8
Documentos
Não foi encontrado nenhum documento associado à publicação.
Publicações Relacionadas

Da mesma revista

Ventricular-arterial coupling in heart failure with preserved ejection fraction: the devil is in the details (2017)
Outra Publicação em Revista Científica Internacional
Fraser, AG; Gillebert, TC; Leite-Moreira AF
Nonlinear biphasic relationship between the time constant tau and load (2000)
Outra Publicação em Revista Científica Internacional
Leite-Moreira AF; Correia Pinto, J; De Hert, SG; Gillebert, TC; Prabhu, SD
Mobile cardiology during the COVID-19 outbreak (2020)
Outra Publicação em Revista Científica Internacional
Leite-Moreira AF; Adao, R
Neuregulin-1 ameliorates right ventricular diastolic dysfunction in pulmonary arterial hypertension (2014)
Outras Publicações
Adao, R; Mendes Ferreira, P; Hamdani, N; Maia Rocha, C; Mendes, MJ; Falcao Pires, I; De Keulenaer, GW; Linke, W; Leite Moreira, AF; Brás-Silva C
Molecular mechanisms underlying the beneficial effects of neuregulin-1 in pulmonary arterial hypertension (2014)
Outras Publicações
Maia Rocha, C; Mendes Ferreira, P; Adao, R; Santos Ribeiro, D; Alves, BS; De Keulenaer, GW; Leite-Moreira AF; Brás-Silva C

Ver todas (26)

Recomendar Página Voltar ao Topo
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Termos e Condições  I Acessibilidade  I Índice A-Z
Página gerada em: 2025-08-20 às 08:29:12 | Política de Privacidade | Política de Proteção de Dados Pessoais | Denúncias